Bradley E. Patt, PhD ‐ Chairman & Chief Executive Officer
Dr. Patt has been chairman of Theracell since it’s inception in 2008 and has served as CEO of the Company since April 2012.
Brad has over 30 years experience as an entrepreneur and executive manager with a strong background in operations, finance, regulatory affairs and R&D of sophisticated leading-edge medical technology products. He has led several enterprises from start-up phase through rapid growth and has experience in executive team development, project management, human resource development, intellectual property as well as interfacing with investors, shareholders, advisors, customers, and commercial, industrial, academic, regulatory, and governmental partners.
Brad founded several high tech ventures since 1997. He previously was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in preclinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in densebreasted women.
Brad is also cofounder and Director of EVO Worldwide, Inc. an advanced medical diagnostic imaging systems company; DxRay, Inc. an advanced digital xray detection company; Photon Imaging, Inc. a technology incubator; and Radiant Detector Technologies, Inc., sold to Seiko of Japan in 2005 now operating as Hitachi High Technology, USA, Inc. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.
Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and 17 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.
Andrew J. Carter, PhD ‐ Chief Technology Officer
Andy has worked with TheraCell as Chief Technology Officer since March 2011 and has more than 30 years leadership experience in the medical device industry and is an expert in orthobiologics, orthopaedics, and biomaterials with more than 30 US patents and patent applications.
Previous experience includes being the founder and President of Accent Biomedical, a provider of innovation services, and Chief Technology Officer at Anika Therapeutics, NASDAQ listed developer of hyaluronic acid based products for orthopedics, ophthalmics and aesthetic dermatology. Prior to this he was Vice President R&D and General Manager at Spine Wave Inc. a Connecticut based start up spine company. There he was responsible for development of injectable nucleus replacement and other motion preserving technologies. Andy spent over twenty years at Smith & Nephew, both in the US and UK. As Group Director of R&D at Smith & Nephew Endoscopy in Boston, USA he led 80+ engineers developing implants, RF and mechanical resection systems, fluid management systems for arthroscopy and endoscopy applications. He also led the company’s successful efforts to improve the effectiveness of the product development process. As Program Manager for Orthopedics and Endoscopy and Head of Materials Research at Smith & Nephew’s Group Research Center in York, UK he formulated and led long term research programs in orthopedics, spine and endoscopy, setting up joint ventures in tissue engineering and collaborative research programs with numerous universities.
Nelson Scarborough, PhD ‐ Chief Scientific Officer
Nelson is an expert in the bone graft field who has extensive experience in orthopedic research, product development and tissue banking. He is a member of the American Association of Tissue banks (AATB) and has over 30 issued US patents, numerous publications in spine and orthopedic journals and presentations at various societies.
Nelson began working with TheraCell in 2013 and has contributed his creativity, knowledge and expertise to conceive and develop several of our new products and road map. His name recognition, experience and scientific acumen make him a key asset for TheraCell.
Previously Nelson was Assistant Professor, Department of Orthopaedics and Director of the University of Florida Tissue Bank from 1987-1992 where he developed a deep understanding of tissue processing and bone biology. In 1993 he joined Osteotech, Inc. (now Medtronic) where his research on bone grafting led to the development of Grafton® Putty, Flex, Crunch and Matrix bone grafts. These products remain market leaders based on extensive research demonstrating their performance.
From 2001-2006 Nelson developed minimally invasive interventional and diagnostic spine products for Smith & Nephew, then was responsible for the development of the Progenix® bone grafts for Medtronic from 2006-2008.
Prior to joining Theracell in 2013 Nelson returned to Boston as the VP R&D Sports Surgery for Covidien.